|Table of Contents|

Expression and clinical significance of Myo1E in pancreatic ductal adenocarcinoma tissues

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 22
Page:
4323-4328
Research Field:
Publishing date:

Info

Title:
Expression and clinical significance of Myo1E in pancreatic ductal adenocarcinoma tissues
Author(s):
ZHU Xiaojing1; SHI Jiawen2; GUO Wenwen1; WANG Yan1
1.Department of Pathology,the Second Affiliated Hospital of Nanjing Medical University,Jiangsu Nanjing 210009,China;2.Pathology Teaching and Research Unit,School of Medicine,Nantong University ＆ Department of Clinical Biobank,Nantong University Affiliated Hospital,Jiangsu Nantong 226001,China.
Keywords:
pancreatic ductal adenocarcinoma; Myo1E; PD-L1; prognosis
PACS:
R735.9
DOI:
10.3969/j.issn.1672-4992.2024.22.017
Abstract:
Objective:Analysis of the expression and clinical significance of myosin 1E (Myo1E) in pancreatic ductal adenocarcinoma (PDAC) tissues.Methods:The expression level of Myo1E mRNA in PDAC tissues and its relationship with prognosis and immune checkpoints were analyzed using the next-generation sequencing data of PDAC in the online cancer genome mapping database,and the clinical significance of Myo1E protein expression and its correlation with the immune checkpoint PD-L1 were analyzed by immunohistochemistry staining using PDAC microarray.Results:The expression of Myo1E mRNA and protein in PDAC tissues was significantly higher than that in benign pancreatic tissues,and was related to the poor prognosis of patients.Myo1E protein expression was associated with tumor diameter (P=0.004),lymph node metastasis (P＜0.001),invasion of surrounding tissues (P=0.008),clinical stage (P＜0.001).Survival analysis showed that Myo1E protein was expressed in PDAC tissues and was an independent risk factor for patient prognosis (HR:1.686,P=0.010),and was linearly positively correlated with the expression of PD-L1 (r=0.388,P＜0.001).Conclusion:Myo1E is an independent risk factor for patient prognosis in PDAC tissues and may be a potential target for immunotherapy.

References:

［1］LOLA RAHIB,BENJAMIN D SMITH,RHONDA ALZENBERG,et al.Projecting cancer incidence and deaths to 2030:the unexpected burden of thyroid,liver,and pancreas cancers in the United States［J］.Cancer Res,2014，74(11):2913-2921.
［2］KIBERLY D MILLER,LETICIA NOGUEIRA,THERESA DEVASIA,et al.Cancer treatment and survivorship statistics,2022［J］.CA Cancer J Clin,2022，72(5):409-436.
［3］REBECCA L,SIEGEL MPH,KIMBERLY D,et al.Cancer statistics,2023［J］.CA Cancer J Clin,2023，73(1):17-48.
［4］PINGPING SUN,HUI ZHANG,JIAWEN SHI,et al.KRTCAP2 as an immunological and prognostic biomarker of hepatocellular carcinoma［J］.Colloids Surf B Biointerfaces，2023，222:113124.
［5］CHENWEI LI,ZEFANH TANG,WENJIE ZHANG,et al.GEPIA2021:integrating multiple deconvolution-based analysis into GEPIA［J］.Nucleic Acids Res,2021，49(1):242-246.
［6］RUSSELL E MCCONNELL,MATTHEW J TYSKA.Leveraging the membrane-cytoskeleton interface with myosin-1［J］.Trends Cell Biol,2010，20(7):418-426.
［7］JACK CHENG,ALEXANDRE GRASSART DAVID G DRUBIN.Myosin 1E coordinates actin assembly and cargo trafficking during clathrin-mediated endocytosis［J］.Mol Biol Cell,2012，23(15):2891-2904.
［8］MICHAEL J GREENBERG,E MICHAEL OSTAP.Regulation and control of myosin-I by the motor and light chain-binding domains［J］.Trends Cell Biol,2013，23(2):81-89.
［9］JESSICA L,OUDERKIRK-PECONE,GREGORY J GORECZNY,et al.Myosin 1e promotes breast cancer malignancy by enhancing tumor cell proliferation and stimulating tumor cell de-differentiation［J］.Oncotarget,2016，7(29):46419-46432.
［10］ROBIN M HALLETT,ANNA DVORKIN GHEVA,ANITA BANE,et al.A gene signature for predicting outcome in patients with basal-like breast cancer［J］.Sci Rep,2012，2:227.
［11］IGNACIA JUSUE TORRES,RICHIES TLV,JULIO C RICARTE FILHO,et al.Myo1e overexpression in lung adenocarcinoma is associated with increased risk of mortality［J］.Sci Rep,2023，13(1):4107.
［12］JU DONG YANG,SO YOUNG SEOL,SUN-HEE LEEM,et al.Genes associated with recurrence of hepatocellular carcinoma:integrated analysis by gene expression and methylation profiling［J］.J Korean Med Sci,2011，26(11):1428-1438.
［13］CHRISTOPHER BUCCITELLI,MATTHIAS SELBACH.mRNAs,proteins and the emerging principles of gene expression control［J］.Nat Rev Genet,2020，21(10):630-644.
［14］HE STOFFLER，C RUPPERT,J REINHARD,et al.A novel mammalian myosin I from rat with an SH3 domain localizes to Con A-inducible,F-actin-rich structures at cell-cell contacts［J］.J Cell Biol,1995，129(3):819-830.
［15］JOEL B HEIM,EDWIN J SQUIREWELL，ANCILLA NEU,et al.Myosin 1E interacts with synaptojanin-1 and dynamin and is involved in endocytosis［J］.FEBS Lett,2007，581(4):644-650.
［16］JA SWANSON,MT JOHNSON,K BENINGO,et al.A contractile activity that closes phagosomes in macrophages［J］.J Cell Sci,1999，112(Pt 3):307-316.
［17］MIRA KRENDEL,SANGWON V KIM,TIM WILLINGER,et al.Disruption of Myosin 1e promotes podocyte injury［J］.J Am Soc Nephrol,2009，20(1):86-94.
［18］YUN LIANG，HANSPETER NIEDERSTRASSER,MARC EDWARDS,et al.Distinct roles for CARMIL isoforms in cell migration［J］.Mol Biol Cell,2009，20(24):5290-5305.
［19］XIA JIN,WENJING WANG,JIANHUA MAO,et al.Overexpression of Myo1e in mouse podocytes enhances cellular endocytosis,migration,and adhesion［J］.J Cell Biochem,2014，115(2):410-419.
［20］JESSICA L ORDERKIRK，MIRA KRENDEL.Myosin 1e is a component of the invadosome core that contributes to regulation of invadosome dynamics［J］.Exp Cell Res,2014，322(2):265-276.
［21］SEBASTIAN MAXEINER,NIAN SHI,CARMEN SCHALLA,et al.Crucial role for the LSP1-myosin1e bimolecular complex in the regulation of Fcgamma receptor-driven phagocytosis［J］.Mol Biol Cell,2015，26(9):1652-1664.
［22］JESSICA L ORDERKIRK，MIRA KRENDEL.Non-muscle myosins in tumor progression,cancer cell invasion,and metastasis［J］.Cytoskeleton (Hoboken),2014，71(8):447-463.
［23］SHRUTHI NARAYANAN,SILVE VICENT,MARIANO PONZ-SARVISE.PDAC as an immune evasive disease:Can 3D model systems aid to tackle this clinical problem［J］.Front Cell Dev Biol,2021，9:787249.
［24］ABDULLAHI ALAUSA,KHADIJAT AYODEJI LAWAL,OLUWAKEMLI ARINOLA BABATUNDE,et al.Overcoming immunotherapeutic resistance in PDAC:SIRPalpha-CD47 blockade［J］.Pharmacol Res,2022，181:p.106264.
［25］GRAZIANA DIGIACOMO,FRANCESCO VOLTA,INGID GARAJOVA,et al.Biological hallmarks and new therapeutic approaches for the treatment of PDAC［J］.Life (Basel),2021，11(8)：843-854.
［26］JOSE BASELGA.Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer［J］.Oncologist,2011，16（Suppl 1）:12-19.
［27］DORTA E KUCZEK,ANNE METTE H LARSEN,MARIE-LOUISE THORSETH,et al.Collagen density regulates the activity of tumor-infiltrating T cells［J］.Immunother Cancer,2019，7(1):68.
［28］JOEL B HEIM,EDWIN J SQUIREWELL,ANCILLA NER,et al.Myosin-1E interacts with FAK proline-rich region 1 to induce fibronectin-type matrix［J］.Proc Natl Acad Sci USA,2017，114(15):3933-3938.
［29］ERIC M ANDERSON,SHANT THOMASSIAN,JUN GONG,et al.Advances in pancreatic ductal adenocarcinoma treatment［J］.Cancers (Basel),2021，13(21)：5510-5521.

Memo

Memo:
-
Last Update: 1900-01-01